Previous 10 | Next 10 |
Exelixis ([[EXEL]] +2.6%) announces that the FDA has approved its CABOMETYX (cabozantinib) drug in combination with Bristol-Myers Squibb's ([[BMY]] +1.2%) OPDIVO (nivolumab) for treating patients with advanced renal cell carcinoma ((RCC)) in the first-line setting.The...
Exelixis ([[EXEL]] +2.6%) announces that the FDA has approved its CABOMETYX (cabozantinib) drug in combination with Bristol-Myers Squibb's ([[BMY]] +1.2%) OPDIVO (nivolumab) for treating patients with advanced renal cell carcinoma ((RCC)) in the first-line setting.The...
– FDA approval based on CheckMate -9ER trial, in which the combination of CABOMETYX and OPDIVO significantly improved overall survival while doubling progression-free survival and objective response rate versus sunitinib as a first-line treatment for patients with advanced RC...
Today, we look back in on mid-cap oncology concern Exelixis. Sales in 2020 were impacted by the pandemic but the company gave some encouraging guidance for 2021 this week. We revisit our investment case on Exelixis in the paragraphs below. For further details see: Evalua...
Exelixis, Inc. (EXEL) 39th Annual J.P. Morgan Healthcare Conference Transcript January 11, 2021 5:20 PM ET Executives Mike Morrissey - President and CEO Analysts Ray Zhong - J.P. Morgan Presentation Ray Zhong Good afternoon, everyone. My name is Ray Zhong and I am a member of the J.P. Morgan ...
Exelixis (EXEL) announces preliminary results for Q4, FY 2020, and financial guidance for FY 2021.Q4 and FY20 total revenues of $270M and $988M, resp.Q4 and FY20 net product revenues of $200M and $741M, resp.FY2021 net product revenue guidance of $950M to $1,050M.FDA approval and commercial l...
– Cabozantinib Franchise Preliminary Net Product Revenue of $200 million for the Fourth Quarter 2020, and $741 million for the Full Year 2020 – – Full Year 2021 Net Product Revenue Guidance of $950 million to $1,050 million – ...
– Presentation to be webcast on www.exelixis.com – Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the virtual 39 th ...
Looking For The Top Biotech Stocks To Watch Ahead of 2021? Any investor worth their salt can tell you that biotech stocks have been all the rage this year. The race to fight the coronavirus pandemic has indeed provided a massive tailwind for the industry. In the latest news,...
Exelixis (NASDAQ: EXEL) , founded in 1994, is a commercial stage biotech company with U.S. Food and Drug Administration-approved drugs to treat advanced cases of thyroid, kidney, and liver cancer. Its lead drug goes by the medical name of cabozantinib, but uses the marketing brand n...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...